IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation

[1]  M. Hattori,et al.  Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells , 2015, Cell.

[2]  C. Gabay,et al.  Regulation and function of interleukin‐36 cytokines in homeostasis and pathological conditions , 2015, Journal of leukocyte biology.

[3]  M. Neurath,et al.  IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis , 2015, Tissue barriers.

[4]  B. Finlay,et al.  Citrobacter rodentium: infection, inflammation and the microbiota , 2014, Nature Reviews Microbiology.

[5]  F. Rosenbauer,et al.  TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells , 2014, Nature Immunology.

[6]  Markus F. Neurath,et al.  Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.

[7]  P. Rutgeerts,et al.  Targeting TNF-α for the treatment of inflammatory bowel disease , 2014, Expert opinion on biological therapy.

[8]  Alessandro Borghi,et al.  Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases: Pathophysiology, Clinical Features, and Therapy , 2014, Inflammatory bowel diseases.

[9]  M. Gresnigt,et al.  Biology of IL-36 cytokines and their role in disease. , 2013, Seminars in immunology.

[10]  C. Garlanda,et al.  The interleukin-1 family: back to the future. , 2013, Immunity.

[11]  S. Melgar,et al.  Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis , 2013, Nature Immunology.

[12]  L. Joosten,et al.  The IL‐36 receptor pathway regulates Aspergillus fumigatus‐induced Th1 and Th17 responses , 2013, European journal of immunology.

[13]  W. Leonard,et al.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. , 2013, Immunity.

[14]  S. Melgar,et al.  Natural Killer Cells Protect against Mucosal and Systemic Infection with the Enteric Pathogen Citrobacter rodentium , 2012, Infection and Immunity.

[15]  S. Werner,et al.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. , 2012, The Journal of clinical investigation.

[16]  F. Sallusto,et al.  IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. , 2012, Blood.

[17]  Patrick T. Walsh,et al.  Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice , 2012, PloS one.

[18]  P. Rutgeerts,et al.  New Drug Therapies on the Horizon for IBD , 2012, Digestive Diseases.

[19]  B. Medoff,et al.  IL-36α Exerts Pro-Inflammatory Effects in the Lungs of Mice , 2012, PloS one.

[20]  P. Henderson,et al.  The rising incidence of paediatric-onset inflammatory bowel disease , 2012, Archives of Disease in Childhood.

[21]  S. Melgar,et al.  The Sphingosine-1-Phosphate Analogue FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen Citrobacter rodentium , 2012, Infection and Immunity.

[22]  C. Dunne,et al.  Rapid rise in incidence of Irish paediatric inflammatory bowel disease , 2012, Archives of Disease in Childhood.

[23]  L. Joosten,et al.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist , 2012, Proceedings of the National Academy of Sciences.

[24]  H. Dinh,et al.  IL-36R ligands are potent regulators of dendritic and T cells. , 2011, Blood.

[25]  C. Gabel,et al.  Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity , 2011, The Journal of Biological Chemistry.

[26]  A. Smahi,et al.  Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.

[27]  R. Xavier,et al.  Genetics and pathogenesis of inflammatory bowel disease , 2011, Nature.

[28]  S. Travis,et al.  IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.

[29]  N. Warner,et al.  The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. , 2011, Immunity.

[30]  B. Medoff,et al.  Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. , 2011, American journal of respiratory cell and molecular biology.

[31]  Leonore A. Herzenberg,et al.  Two physically, functionally, and developmentally distinct peritoneal macrophage subsets , 2010, Proceedings of the National Academy of Sciences.

[32]  H. Dinh,et al.  Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation , 2007, The Journal of experimental medicine.

[33]  L. Herrinton,et al.  Clustering of Inflammatory Bowel Disease With Immune Mediated Diseases Among Members of a Northern California-Managed Care Organization , 2007, The American Journal of Gastroenterology.

[34]  Philip Smith,et al.  Infection with a Helminth Parasite Prevents Experimental Colitis via a Macrophage-Mediated Mechanism1 , 2007, The Journal of Immunology.

[35]  L. Hennighausen,et al.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. , 2007, Immunity.

[36]  C. Bernstein,et al.  The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. , 2005, Gastroenterology.

[37]  M. Zeitz,et al.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. , 2005, Gastroenterology.

[38]  H. Ogata,et al.  Cytokine and anti-cytokine therapies for inflammatory bowel disease. , 2003, Current pharmaceutical design.

[39]  H. Ogata,et al.  Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. , 2003, Journal of gastroenterology.

[40]  W. Falk,et al.  Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. , 1996, Gut.

[41]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[42]  A. Caraffa,et al.  IL-36 a new member of the IL-1 family cytokines. , 2012, Journal of biological regulators and homeostatic agents.

[43]  Larry L. Constantine,et al.  Back to the future , 2001, CACM.

[44]  H. Moser.  [Pathophysiology, clinical features and therapy of Sudeck's disease]. , 1953, Langenbecks Archiv fur klinische Chirurgie ... vereinigt mit Deutsche Zeitschrift fur Chirurgie.